ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Videos Lung Cancer

US Could Save Nearly $1 Billion With Pembrolizumab Dosing Change

In this video, Daniel A. Goldstein, MD, of the Davidoff Cancer Center in Israel, discusses a study that found that a change to weight-based pembrolizumab dosing in first-line PD-L1–positive non–small-cell lung cancer could save nearly $1 billion in US healthcare expenditures.

Videos Lung Cancer

This video reviews pseudoprogression in non–small-cell lung cancer, including the incidence of this phenomenon and treatment considerations when it arises.

This video reviews the use of PD-L1 testing in selecting patients for frontline lung cancer treatment with pembrolizumab and examines which patients might not be appropriate for immunotherapy.

This video reviews immunotherapy options now available for the treatment of lung cancer across different lines of therapy.

This video highlights a study that tested an alternative maintenance strategy determined by response to induction chemotherapy for patients with advanced non-squamous non–small-cell lung cancer.

This video examines how a change to weight-based pembrolizumab dosing in first-line PD-L1–positive lung cancer could save nearly $1 billion in US healthcare costs.

This video examines a phase II trial that studied maintenance pembrolizumab in extensive-stage small-cell lung cancer.

This video reviews options for radiation therapy in the treatment of small-cell lung cancer, including dosing frequency and use of thoracic and cranial irradiation in extensive-stage disease.

Pages

Subscribe to Videos Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.